Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets

Bernardsville, New Jersey (ots/PRNewswire) -

Anima Biotech today announced an agreement with Lilly for the
discovery and development of translation inhibitors for several
target proteins by using Anima's Translation Control Therapeutics
platform.

(Logo:
https://mma.prnewswire.com/media/721538/Anima_Biotech_Logo.jpg )

The multi-year agreement is structured as an exclusive
collaboration around several undisclosed Lilly targets. Anima will
use its technology platform to discover lead candidates that are
translation inhibitors of the Lilly targets. Lilly will be
responsible for clinical development and commercialization of
products resulting from the collaboration.

Under the terms of the agreement, Anima will receive $30 million
in upfront payments and $14 million in research funding. Anima is
eligible to receive up to $1.05 billion if all future development and
commercial milestones are achieved. Anima will additionally be
entitled to low to mid single-digit tiered royalties on sales of any
Lilly products resulting from the collaboration.

"We are excited to collaborate with Lilly in the discovery of new
drugs for some of the world's most challenging diseases. Small
molecule drugs work by binding to disease-causing proteins to modify
their chemical activity but most proteins lack accessible binding
sites and as result, many diseases remain without effective
treatments. Anima's Translation Control Therapeutics platform is a
new strategy against these undruggable target proteins. Rather than
attempt to drug them after they are already made, we discover drugs
that work one step before, by inhibiting (decreasing) or increasing
the actual production by ribosomes of those proteins. This different
approach is based on our novel science and patented technology and we
believe it can lead to many new drugs," said Yochi Slonim, Anima
Biotech's co-founder and CEO.

About Anima Biotech:

Anima Biotech is pioneering Translation Control Therapeutics, a
new class of drugs that specifically control protein translation as a
novel strategy against hard and undruggable targets. Strategically
structured for collaborations with multiple pharma partners, Anima's
cloud based platform combines new biology with proprietary image
analysis and high performance big data software. Its underlying
technology is protected by 5 granted patents and its science is
backed by 14 peer-reviewed publications that resulted from a network
of 17 academic collaborations. The platform was validated by Anima's
fast growing pipeline programs in multiple therapeutic areas
including Fibrosis (https://www.animabiotech.com/programs/lung-fibros
is-collagen-i-translation-inhibitors), Viral infections, Oncology and
Neuroscience.

For more information visit http://www.animabiotech.com

Clara Assouline

anima@animabiotech.com

+972-72-214-8770

ots Originaltext: Anima Biotech
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Anima Biotech, übermittelt durch news aktuell